Poseida Therapeutics Inc Ordinary Shares PSTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PSTX is a good fit for your portfolio.
News
-
Poseida Therapeutics Announces Strong Lineup of Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting
-
Poseida Therapeutics Hosts Gene Therapy R&D Day Highlighting New Scientific Advancements and Pipeline Focus
-
Poseida Therapeutics Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-ALLO1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple Myeloma
-
Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Poseida Therapeutics Appoints Syed Rizvi, M.D., as Chief Medical Officer
-
Poseida Therapeutics to Present at H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
-
Poseida Therapeutics Announces FDA Orphan Drug Designation Granted to P-BCMA-ALLO1 for the Treatment of Multiple Myeloma
-
Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2023
Trading Information
- Previous Close Price
- $2.05
- Day Range
- $2.03–2.14
- 52-Week Range
- $1.54–4.27
- Bid/Ask
- $2.12 / $2.25
- Market Cap
- $205.52 Mil
- Volume/Avg
- 461,299 / 729,730
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.86
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Poseida Therapeutics Inc is a clinical-stage biopharmaceutical company focused on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with a high unmet medical need. It has built a pipeline of autologous and allogeneic chimeric antigen receptor T cell, or CAR-T, product candidates, initially focused on the treatment of hematological malignancies and solid tumours.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 330
- Website
- https://www.poseida.com
Comparables
Valuation
Metric
|
PSTX
|
VOR
|
CELC
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.89 | 0.76 | 2.91 |
Price/Sales | 2.86 | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
Metric
|
PSTX
|
VOR
|
CELC
|
---|---|---|---|
Quick Ratio | 3.10 | 8.81 | 12.78 |
Current Ratio | 3.18 | 9.04 | 13.43 |
Interest Coverage | −13.22 | — | −12.43 |
Quick Ratio
PSTX
VOR
CELC
Profitability
Metric
|
PSTX
|
VOR
|
CELC
|
---|---|---|---|
Return on Assets (Normalized) | −35.56% | −41.83% | −35.57% |
Return on Equity (Normalized) | −76.51% | −51.69% | −49.08% |
Return on Invested Capital (Normalized) | −44.37% | −47.03% | −39.21% |
Return on Assets
PSTX
VOR
CELC
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Hyjwhftl | Kvrw | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Gwvlysglt | Jtxwj | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Wpsgcwflh | Hrpsrg | $97.8 Bil | |
MRNA
| Moderna Inc | Ydprlqd | Dlt | $41.3 Bil | |
ARGX
| argenx SE ADR | Vvyrzzk | Qqy | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Glnhtzptb | Krjn | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Rqbsrmzv | Hfsrpyd | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Fvsqxjnt | Fwwvjfm | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Kjrqqphkb | Gngptl | $12.5 Bil | |
INCY
| Incyte Corp | Mxrkbgr | Zjznycl | $11.6 Bil |